Your session is about to expire
← Back to Search
Pembrolizumab for Lung Cancer
Study Summary
This trial is testing whether blood tests can show how well pembrolizumab is working against cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.My recent blood and organ function tests are within normal ranges.I can start treatment within 2 days of joining the trial.I haven't had chemo or immunotherapy for advanced lung cancer but may have had it for earlier stages.I cannot take pembrolizumab due to an active infection, autoimmune disease, need for immunosuppressants, severe immune reactions, or allergy to it.My cancer shows a PD-L1 level of 1% or higher.I am not currently receiving any other cancer treatments.I've had recent scans of my chest, abdomen, pelvis, and brain to document my cancer.My lung cancer does not have EGFR or ALK mutations, or I have squamous cell lung cancer.I had major surgery over 28 days ago and my wound has healed.I had cancer before, but it won't affect this trial's treatment.I have recovered from side effects of my previous cancer treatments.I agree to use birth control if I or my partner can become pregnant.I have brain metastases but am stable on low-dose steroids or have no symptoms.I am fully active or can carry out light work.I can be treated with pembrolizumab and understand it might not be covered everywhere.My lung cancer is confirmed and has spread, but I can't have surgery or targeted radiation.My cancer can be measured by scans according to RECIST 1.1.
- Group 1: Pembrolizumab + standard platinum-based chemotherapy
- Group 2: Pembrolizumab alone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the most popular indications for Pembrolizumab?
"Pembrolizumab is an immunotherapy medication that can be used to shrink or slow the growth of various types of cancer, such as malignant neoplasms and microsatellite instability high."
How many people with the medical condition are being asked to participate in this research study?
"Unfortunately, this study is not enrolling patients at the moment. However, it was updated recently on April 7th, 2022. For individuals interested in other studies, there are 2096 trials actively recruiting for nsclc and 1000 pembrolizumab clinical trials also searching for participants."
Could you please provide an overview of Pembrolizumab's safety record?
"While Phase 2 trials don't have extensive data supporting efficacy, the available information suggests that Pembrolizumab is safe."
What is the Pembrolizumab research landscape like?
"City of Hope first studied pembrolizumab in 2010 and, since then, there have been 250 completed trials. At the moment, there are 1000 clinical trials underway with many taking place in Hamilton, British Columbia."
Are we still enrolling patients for this experiment?
"This study is not currently looking for new participants, as seen by the posting and last edit dates. However, there are 2096 other trials for patients with non-small cell lung carcinoma (nsclc) and 1000 trials involving Pembrolizumab that are actively recruiting."
Are the sites for this trial widely dispersed?
"There are 6 running for this study such as Juravinski Cancer Centre at Hamilton Health Sciences in Hamilton, BCCA - Vancouver Cancer Centre in Vancouver, and The Sidney Kimmel Comprehensive Cancer Centre in Baltimore. Other locations include the Mayo Clinic in Rochester, Seattle Cancer Care Alliance, and Dana-Farber Cancer Institute in Boston."
Share this study with friends
Copy Link
Messenger